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INTRODUCTION 
Non-alcoholic fatty liver (NAFLD) is a clinic-
pathological diagnosis in which more than 5% of 
hepatocytes demonstrate macrovesicular steatosis in an 
individual without a significant history of alcohol intake. 
In recent years NAFLD, the most common form of liver 
disease, has been recognized as the hepatic manifestation 
of the metabolic syndrome.1 NAFLD occurs across all 
age groups and ethnicities. The reported prevalence of 
NAFLD varies widely depending on the population 
studied and the definition used. The estimated worldwide 
prevalence of NAFLD ranges from 6.3% to 33% with a 
median of 20% in the general population, based on a 
variety of assessment methods.2-4 Primary NAFLD is 
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ABSTRACT 
Background: Nonalcoholic fatty liver disease (NAFLD) is a reversible condition of fat accumulation that is 
associated with liver inflammation and can disrupt the normal activity of the liver. People with a diagnosis of NAFLD 
have a higher risk of all- cause mortality than the general population. The purpose of the present study was to 
determine, the efficacy of orlistat in the treatment of patients with NAFLD. 
Methods: This semi-experimental study was performed on 45 fatty liver patients of the gastroenterology clinic of 
Imam Khomeini Hospital in Ardabil city in April 2016 to April 2017. Data was collected by a checklist which 
included demographic and clinical data such as age, sex, body mass index (BMI), alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), triglyceride (TG), cholesterol and result of ultrasound before and after orlistat 
consumption. 
Results: The mean decrease in the variables examined was as follows: weight 8.3 kg, BMI 3.5 kg/m2, ALT 31.6 U/l, 
AST 18.1 U/l, cholesterol 15.5 mg/dl and TG 33.1 mg/dl. All of the upper indexes were decreased significantly 
following received drug. 
Conclusions: Orlistat therapy was associated with significant decreases in ALT, AST, TG and cholesterol level. 
Orlistat is effective in weight loss, body mass index reduction and can be used to treat non-alcoholic fatty liver 
disease. 
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related to insulin resistance and thus frequently appears 
as part of the metabolic changes that accompany obesity, 
diabetes, and hyperlipidemia.5 The usual management of 
NAFLD includes gradual weight reduction and physical 
activity, leading to an improvement in serum liver 
enzyme levels, reduced hepatic fatty infiltration and in 
some cases a reduced degree of hepatic inflammation and 
fibrosis.6 Although lifestyle modification is sufficient in 
many patients, resistant cases of NAFLD may require 
pharmacologic therapy. Candidate medications for the 
treatment of NAFLD should lead to weight loss, 
decreased free fatty acid (FFA) flux to the liver, and 
improved insulin sensitivity, without hepatotoxic adverse 
effects.7 Orlistat, a gastrointestinal lipase inhibitor, is 
useful in the treatment of obesity and type 2 diabetes 
mellitus. Gastric and pancreatic lipases are enzymes that 
play a main role in the digestion of dietary fat. Orlistat, a 
semisynthetic derivative of lipstatin, is a potent and 
selective inhibitor of these enzymes; it exerts its effect 
within the gastrointestinal (GI) tract. Orlistat acts by 
binding covalently to the serine residue of the active site 
of gastric and pancreatic lipases. When administered with 
fat-containing foods, orlistat partially inhibits hydrolysis 
of triglycerides, thus reducing the subsequent absorption 
of monoglycerides and FFA.8 Therefore, the purpose of 
this study was to evaluate the effect of orlistat in the 
treatment of non-alcoholic fatty liver disease in patients 
of Ardabil city hospital. 
Objectives 
The objectives of the present study were to compare the 
efficacy of orlistat in the treatment of non-alcoholic fatty 
liver disease in patients with grade II and III fatty liver. 
METHODS 
Study design 
This study was semi experimental study. 
Procedure 
After approval of the project at the Ethics Committee of 
Biological Research in Ardebil University, this study was 
performed on 45 patients with grade II and III fatty liver 
in ultrasound exam in which were selected by a 
gastroenterologist from among the patients referred to the 
Imam Khomeini Hospital in April 2016 to April 2017. An 
ultrasound examination was carried out at the beginning 
and at the end of the study by the same person and the 
same device.  
The diet included 100 kJ/day for ideal body weight, with 
an emphasis on reduced intake of both fat (-25% of daily 
calories) and simple carbohydrates. all patients were 
advised to avoid overeating, eating high-fat and high-
energy foods during the study and were encouraged to 
perform physical activity 2 to 3 times a week (30 minutes 
of walking at 4 to 5 km/h). The nutritionist interviewed 
all study participants at the time of their monthly clinic 
visit. The patients received orlistat (120 mg before lunch 
and dinner) for three months.  
Data was collected by a checklist containing 
demographical information such as age, sex and weight.  
Inclusion criteria 
Non-alcoholic fatty liver patients with grade II and III 
that approved by an ultrasound exam and patients who 
signed the consent to diet were included in the study. 
Exclusion criteria 
Patients with diabetes mellitus, chronic viral hepatitis, 
alcoholic fatty liver disease and pregnant women were 
excluded. 
Efficacy measures 
Liver ultrasound condition, body mass index (BMI), 
serum aspartate and alanine aminotransferase (AST and 
ALT), cholesterol and triglyceride (TG) levels were 
assessed at baseline and at the completion of the study. 
Statistical analysis  
The collected data were analyzed by SPSS software 
version 22. Data are presented as mean±SD. Paired t-tests 
were used to evaluate within-group changes from pre and 
post-treatment. P value less than 5% was considered 
statistically significant.  
RESULTS 
Forty-five patients with NAFLD received orlistat. Ninety- 
three percent of the patients were obese (BMI ≥30 kg/m2), 
53.3% of patients were female and the rest were male. 
The mean age was 45.8±9.7 years. Forty-two percent of 
the patients were 41 to 50 age (Table 1). 
Table 1: Demographic parameter. 
Variables Number Percentage (%) 
Sex 
Female 24 53.3 
Male 21 46.7 
Age (in 
years) 
>30 3 6.7 
31-40 9 20 
41-50 19 42.2 
51-60 10 22.2 
<60 4 8.9 
Following three months therapy with orlistat, body mass 
index and weight decreased significantly. The mean 
decrease in the variables examined was as follows: weight 
loss 8.3 kg, BMI 3.5 kg/m2, ALT 31.6 U/l, aspartate AST 
18.1 U/l, cholesterol 15.5 mg/dl and TG 33.1 mg/dl 
(Table 2). At the beginning of the study, all patients had 
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grade II or III fatty liver in ultrasound exam. Three 
months after treatment, 24% had normal ultrasonography, 
53% had first grade fatty liver, and 22% had grade II fatty 
liver (Table 3). 
Table 2: Mean BMI, weight and biochemical tests pre- and post-treatment. 
Variables Pre-treatment Post-treatment difference P value 
BMI in kg/m2 (normal, 20–25) 35.2±3.4 (24-40) 31.8±3.2 (22-37) 3.5±1.2 0.00 
Weight in kg 100±14.8 (75-138) 91.8±14.3 (69-116) 8.3±3.4 0.00 
Triglyceride level in mg/dl 
(normal, 50–175) 
258.5±68.1 (94-327) 225.3±74.5 (29-313) 33.1±40.1 0.00 
Cholesterol level in mg/dl  
(normal, 150–200) 
222.4±61.6 (146-317) 206.8±61.2 (128-312) 15.5±13.3 0.00 
ALT level in U/l (normal, 5–39) 73.6±33 (26-216) 42±26.2 (5-154) 31.6±13.7 0.00 
AST level in U/l (normal, 5–40) 41.5±14.8 (19-75) 23.4±13.4 (2-57) 18.1±5.8 0.00 
Note: For all variables, data are presented as mean ±SD, with the range in parentheses. 
Table 3: Frequency of NAFLD grade in pre- and post-treatment. 
Time of study 
Fatty liver grade 
P value 
3 2 1 0 
N  % N  % N  % N  %  
Base line 23 51.1 22 48.9 - - - - 
0.02 
End of study - - 10 22.2 24 53.3 11 24.4 
 
DISCUSSION 
The prevalence of NAFLD is rapidly increasing 
worldwide along with the increase in obesity and type 2 
diabetes.9 Studies show that NAFLD is often associated 
with insulin resistance, obesity, diabetes mellitus, 
hyperlipidemia, visceral adiposity and other cardio-
metabolic diseases.1,10-12 
Orlistat, a reversible inhibitor of gastric and pancreatic 
lipases, has been approved by the FDA for weight loss. It 
is not absorbed into the circulation and is mainly excreted 
unchanged in the faces. Data suggest that when orlistat 
combined with dietary counseling, approximately 40% of 
treated patients for one year were able to lose up to 10% 
of their body weight.13 Lipase inhibition by orlistat 
prevents the absorption of approximately 30% of energy 
from fat.14,15 Orlistat, as an anti obesity drug, reduces lipid 
levels following a high-fat meal. A study by Gabriel et al 
identified that administration of orlistat suppressed the 
postprandial rise of TG levels in healthy adult volunteers 
following consumption of meals with 50% fats.16 
The present study showed that patients lose up 8.3 kg of 
their body weight after the use of orlistat and their body 
mass index decreased significantly too. In a study by 
Smith et al results showed that orlistat was an effective 
drug to weight loss and reducing metabolic risk factors 
associated with abdominal obesity.17 Other studies 
showed that treatment with orlistat reduced weight and 
improved hyperglycemia in diabetic overweight 
patients.14,18 Finer et al in a study on obese patients for 
one-year, showed that Orlistat group had lower waist 
circumference than the placebo group and weight loss in 
Orlistat group was 14% more than the placebo group.19 In 
the study by Zelber-Sagi et al Weight loss mean with 
orlistat treatment was 7.7 kg, and in the study by Harrison 
et al Orlistat was associated with a significant reduction in 
weight, HbA1c, ALT and AST.7,13 In meta-analysis by 
Wang et al the efficacy and safety of orlistat in the 
treatment of NAFLD and improvements were observed in 
levels of Alanine aminotransferase, aspartate 
aminotransferase, gamma-glut amyl transpeptidase and 
triglycerides. They suggested that orlistat could serve as a 
therapeutic drug in improving biochemical indicators of 
liver damage, suggesting a novel palliative drug for the 
treatment of NAFLD.20  
CONCLUSION 
Significant decreases in ALT, AST, TG and cholesterol 
levels were observed following Orlistat therapy and the 
drug is effective in weight loss and body mass index 
reduction . It seems that orlistat can be used in treatment 
of non-alcoholic fatty liver disease. Using an antioxidant 
such as vitamin E along with orlistat may also help to 
improve the tissues damages in NAFLD. A clinical trial is 
recommended using the combination of the two drugs. 
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